Skip to main content
TipRanks
Go Ultimate75% OFF

ImageneBio (IMA) Stock Price & Analysis

116 Followers

IMA Stock Chart & Stats

$3.47$0.02(0.58%)
At close: 4:00 PM EST
$4$5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$3.34 - $3.58
52-Week Range
$3.34 - $8.32
Previous Close
$3.45
Volume
N/A
Average Volume (3M)
12.27K
Market Cap
$43.22M
Enterprise Value
-$41.38M
Total Cash (Recent Filing)
$126.60M
Total Debt (Recent Filing)
$6.79M
Price to Earnings (P/E)
―
Beta
0.91
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Debt of just $1.3M against $128.1M of equity gives the company a low leverage burden for an early-stage biotech. This reduces near-term solvency pressure and preserves greater flexibility to fund clinical development while it remains pre-commercial.

Meaningful Capital Base

The $142.5M asset base and $128.1M of equity provide a substantial financial foundation relative to the company’s modest debt. That capital base can support ongoing research and development and offers more resilience than a highly leveraged balance sheet.

Reduced Losses

Net losses have improved from roughly $68M in 2022–2023 to $43.3M on a TTM basis, suggesting some cost moderation. Although the company remains unprofitable, this improvement could help extend financial resources if maintained through future development periods.

Bears Say

No Meaningful Revenue

Revenue has declined to zero on a TTM basis, confirming that ImageneBio has not established meaningful operating scale or recurring commercial sales. This leaves the business dependent on successful clinical progress and future financing or partnering to support its operations.

Persistent Large Losses

Large ongoing net losses show that the company remains far from breakeven as a pre-commercial biotech. Continued losses reduce retained capital, limit self-funded investment capacity, and make future financial performance highly dependent on advancing candidates toward commercial value.

Sustained Cash Burn

Persistent negative free cash flow demonstrates that operations consume substantial cash rather than funding themselves. The company therefore remains dependent on external funding, while volatile burn and a 29.7% TTM decline versus the prior annual period increase planning and financing pressure.

ImageneBio News

IMA FAQ

What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.34 and its highest was $8.32 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $43.22M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
ImageneBio released its earnings results on Nov 09, 2026. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.804 by -$0.106.
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 12,456,281 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
ImageneBio reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.804. Following the earnings report the stock price went down -4.03%.
Which hedge fund is a major shareholder of ImageneBio?
Hedge funds hold ImageneBio shares: the largest hedge-fund position in ImageneBio is 70,130,271 shares, and hedge funds increased their holdings by 5.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology